<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2024.1410187</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Variants loci and phenotype correlation of <italic>TRIM8-</italic>related neuro-renal syndrome: three cases reports and literature review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lv</surname> <given-names>Qiu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Niu</surname> <given-names>Yue</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1356216/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname> <given-names>Zhao</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1684888/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name><surname>Qin</surname> <given-names>Jiong</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<xref ref-type="author-notes" rid="fn0004"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/524770/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name><surname>Yang</surname> <given-names>Zhixian</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<xref ref-type="author-notes" rid="fn0004"><sup>&#x2020;</sup></xref>
<xref ref-type="author-notes" rid="fn0005"><sup>&#x2021;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/511595/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Pediatrics, Peking University People&#x2019;s Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Epilepsy Center, Peking University People&#x2019;s Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0006">
<p>Edited by: Roberto Chimenz, University of Messina, Italy</p>
</fn>
<fn fn-type="edited-by" id="fn0007">
<p>Reviewed by: Siddharth Shah, University of Louisville, United States</p>
<p>Giorgia Ceravolo, University College London, United Kingdom</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Zhixian Yang, <email>zhixian.yang@163.com</email></corresp>
<corresp id="c002">Jiong Qin, <email>qinjiong@pkuph.edu.cn</email></corresp>
<fn fn-type="equal" id="fn0004"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
<fn fn-type="other" id="fn0005"><p><sup>&#x2021;</sup>ORCID: Zhixian Yang, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-9649-8725">orcid.org/0000-0002-9649-8725</ext-link></p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1410187</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>09</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Lv, Niu, Xu, Qin and Yang.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Lv, Niu, Xu, Qin and Yang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p><italic>TRIM8</italic>-related neuro-renal syndrome (NRS), caused by pathogenic variants of the <italic>TRIM8</italic> gene, is characterized by epilepsy, developmental delay (DD) and renal disorders. The severity of the neurological effects as well as the presence of renal disorders is variable among patients. Here, we report three additional patients with clinical features compatible with NRS and summarize the association between the variants&#x2019; loci and phenotype of <italic>TIRM8</italic>-related NRS.</p>
</sec>
<sec>
<title>Methods</title>
<p>A retrospective analysis was conducted for three Chinese children with NRS due to <italic>TRIM8</italic> variants identified through whole-exome sequencing (WES). Previous reports of patients with <italic>TRIM8</italic>-related NRS were reviewed systematically. Demographic and clinical data were collected from these patients</p>
</sec>
<sec>
<title>Results</title>
<p>Two <italic>de novo</italic><italic>TRIM8</italic> truncating variants in three NRS patients were identified in our study, including c.1327_c.1328delCCinsTG (p. Arg443&#x002A;) and c.1375C&#x003E;T (p.Gln459&#x002A;). Our three patients all exhibited drug-resistant epilepsy and early-onset DD, and two of whom developed electrical status epilepticus during sleep (ESES). Brain magnetic resonance imaging (MRI) showed periventricular leukomalacia in one patient and normal in the other two. All three patients demonstrated nephrotic range proteinuria (NRP) or nephrotic syndrome (NS) with normal renal function during follow-up. There was a total of 27 patients with <italic>TRIM8</italic>-related NRS have been identified to date. The most common clinical features are renal diseases (89%), DD (89%), followed by epilepsy (78%). 67% of patients eventually progressed to end-stage renal disease (ESRD). Focal seizure was the most frequent seizure type (57%). 52% of patients presented drug-resistant epilepsy. 64% of patients exhibited non-specific brain MRI abnormalities. Brain atrophy was the most common change (50%). Two patients with TRIM8 variants closer to the N-terminal had neurological diseases without renal damage. Five patients with <italic>TRIM8</italic> variants closer to the C-terminal had no severe neurological diseases. Seven patients had Gln459&#x002A; variant which is the most common variant (7/27, 25.9%). The severity of the renal and neurological damage of the seven patients was variable.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This study expands the number of individuals with confirmed NRS due to pathogenic variants in <italic>TRIM8</italic>. Neurological and renal phenotype with the same variant locus differed in their severity. Further research is needed to explore the relationship between genotype and phenotype of <italic>TRIM8</italic> variants.</p>
</sec>
</abstract>
<kwd-group>
<kwd><italic>TRIM8</italic></kwd>
<kwd>neuro-renal syndrome</kwd>
<kwd>epilepsy</kwd>
<kwd>developmental delay</kwd>
<kwd>nephrotic syndrome</kwd>
<kwd>proteinuria</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="16"/>
<page-count count="10"/>
<word-count count="4794"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pediatric Neurology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Truncating variants in <italic>tripartite motif containing 8(TRIM8)</italic> gene (OMIM:606125), firstly described by Allen et al. in 2013 (<xref ref-type="bibr" rid="ref1">1</xref>), are the genetic basis of neuro-renal syndrome (NRS) encompassing renal and neurodevelopmental phenotype (<xref ref-type="bibr" rid="ref2">2</xref>). The disorder shows an autosomal dominant pattern of inheritance. Renal phenotype includes asymptomatic proteinuria, nephrotic-range proteinuria (NRP), nephrotic syndrome (NS), focal segmental glomerulosclerosis (FSGS) and most cases eventually progress to end-stage renal disease (ESRD). Neurodevelopmental phenotype includes epilepsy or epileptic encephalopathy, developmental delay (DD) and autism spectrum disorder (ASD).</p>
<p><italic>TRIM8</italic> gene encodes a protein with 551 amino acids, which are involved in a broad range of biological processes, such as differentiation, proliferation, intracellular signaling, protein quality control, autophagy, and immunity (<xref ref-type="bibr" rid="ref3">3</xref>). The protein contains a RING-finger domain, two B-boxes (B-box1 and B-box2), a coiled-coil domain, and a proline-rich C-terminal region with a nuclear localization signal (NLS) (<xref ref-type="bibr" rid="ref4">4</xref>, <xref ref-type="bibr" rid="ref5">5</xref>). TRIM8 modulates the activity of important cellular proteins through protein&#x2013;protein interactions mediated mainly by the coiled-coil and the C-terminus domains (<xref ref-type="bibr" rid="ref6">6</xref>). Deletion of the C-terminal domain of <italic>TRIM8</italic> can result in protein mislocalization (<xref ref-type="bibr" rid="ref4">4</xref>).</p>
<p>To date, a total of 18 different <italic>TRIM8</italic> truncating variants in 24 NRS patients have been reported in the literatures, and all of them were located in exon 6 (<xref ref-type="bibr" rid="ref2">2</xref>, <xref ref-type="bibr" rid="ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14">7&#x2013;14</xref>). There are no reports referring to the incidence rate of NRS. Previous studies demonstrated that there is a variability in the severity of renal or neurological phenotype. Here, we describe three previously unpublished NRS patients and provide an overview of the literatures to summarize the phenotype&#x2013;genotype relationship of <italic>TRIM8-</italic>related NRS.</p>
</sec>
<sec sec-type="methods" id="sec2">
<label>2</label>
<title>Methods</title>
<sec id="sec3"><label>2.1</label><title>Patients</title><p>Three children with <italic>TRIM8</italic>-related NRS were recruited for this study from Peking University People&#x2019;s Hospital from July 2018 to September 2023. Detailed clinical data were collected from the medical record system, including sex, family history, physical examinations, clinical manifestation (including renal and neurological symptoms), urinalysis, renal biopsy, electroencephalographic (EEG) recordings, brain magnetic resonance imaging (MRI) findings, medication, and prognosis. Follow-up was</p> <p>performed by clinic visits or telephone.</p></sec>
<sec id="sec4">
<label>2.2</label>
<title>Ethics statement</title>
<p>This study was approved by the Biomedical Research Ethical Committee of Peking University People&#x2019;s Hospital. Written informed consent was obtained from the parents for publication of this report.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Molecular genetic testing</title>
<p><italic>TRIM8</italic> gene (Ref Seq NM_030912.2) was performed using trio-based whole exome sequencing (Trio-WES) for all three patients. Sanger sequencing was performed to validate detected variations and determine their parental origin. Variants were classified as &#x201C;pathogenic&#x201D; or &#x201C;likely pathogenic&#x201D; according to the variant interpretation guidelines of American College of Medical Genetics (ACMG) guidelines (<xref ref-type="bibr" rid="ref15">15</xref>).</p>
</sec>
<sec id="sec6"><label>2.4</label><title>Literature review</title><p>A systematic literature search was performed in the PubMed and HGMD electronic databases to extract relevant articles that mainly focused</p> <p>on <italic>TRIM8</italic> variants in epilepsy or nephrotic syndrome up to December 2023. The search terms used were &#x201C;TRIM8&#x201D; AND (&#x201C;epilepsy&#x201D; or &#x201C;proteinuria&#x201D; or &#x201C;nephrotic syndrome&#x201D;). Original research, case reports, and case series were identified. Clinical</p> <p>data of patients with <italic>TRIM8</italic>-related NRS were obtained from these identified studies.</p></sec>
</sec>
<sec sec-type="results" id="sec7">
<label>3</label>
<title>Results</title>
<sec id="sec8">
<label>3.1</label>
<title>Case series</title>
<sec id="sec9">
<label>3.1.1</label>
<title>Patient 1</title>
<p>A now-10-year-old female was born at term following an uneventful pregnancy with birth weight 3,800&#x2009;g. She had no family history of renal or neurological disease. Shortly after birth, the patient was noted to have feeding difficulty. DD was subsequently observed. She could hold her head up at 5&#x2009;months, sit at 11&#x2009;months, crawl at 18 moths and walk unsupported at 28&#x2009;months. Expressive language, especially speech, was particularly impaired, as she was only able to babble a few constant sounds. She developed afebrile hemiconvulsion at 25&#x2009;months. Each seizure ceased within a few seconds to 5&#x2009;min. Physical examination showed generalized hypotonia and mild facial features, including a long philtrum and odontodysplasia. She had no remarkable results of blood biochemistry, ammonia, lactate acid and metabolic disease screening. The EEGs showed marked Rolandic discharges, which was more prominent in the left region, and she was diagnosed with electrical status epilepticus during sleep (ESES). Brain MRI detected no abnormalities. Valproate acid was introduced with seizure-free for 9&#x2009;months. Seizures recurred and worsened despite adding oxcarbazepine at 2&#x2009;years and 10&#x2009;months. Then oxcarbazepine was replaced by levetiracetam. Seizures were poorly controlled despite multiple therapies, including zonisamide, clobazam, lamotrigine and corticosteroids.</p>
<p>Glomerular proteinuria and mild hematuria were noted at 4&#x2009;years and 5&#x2009;months. Proteinuria gradually worsened (24-h proteinuria: 1.556&#x2009;g) with normal serum albumin, cholesterol and creatinine. Renal biopsy revealed minor glomerular abnormalities without deposition of immune complexes by light microscopy and extensive podocyte foot process effacement by electron microscopy. After treatment with enalapril, her proteinuria decreased, but was not in complete remission (24-h proteinuria: 0.96&#x2009;g).</p>
<p>During follow-up, seizures occurred once per year from 7&#x2009;years old, all of which were induced by infective fever. Her speech delay improved due to therapy. At 10&#x2009;years, she exhibited poor abilities in learning, memory and writing tasks (restricted to numbers 1&#x2013;10). Her renal function remained normal up to now.</p>
</sec>
<sec id="sec10">
<label>3.1.2</label>
<title>Patient 2</title>
<p>A now-7-year-old female was born at term following an uneventful pregnancy with birth weight 3,150&#x2009;g. During infancy, the patient was noted to have mild DD. At 1&#x2009;year and 9&#x2009;months, she developed focal seizures with developmental regression after seizure onset. Physical examination showed generalized hypotonia, stereotypic movements without facial deformities. Interictal EEG demonstrated slow background and diffuse spike-and-waves with ESES. Brain MRI showed periventricular leukomalacia. She had a total of three anti-seizure medications (ASMs), including levetiracetam, valproate acid and clonazepam, and continued to have occasional seizures, most of which occurred during infection.</p>
<p>At 1&#x2009;year and 9&#x2009;months, the patient was also noted to have significant proteinuria (protein 2+) and hematuria. At 6&#x2009;years and 9&#x2009;months, urinalysis confirmed nephrotic range proteinuria (protein 3&#x2013;4+). And she developed hypoalbuminemia (26.7&#x2009;g/L) and hyperuricemia. Renal ultrasound, immunoglobulins, complement, anti-nuclear antibodies and anti-double stranded DNA antibodies were all within normal limits. Renal biopsy revealed minor glomerular abnormalities by light microscopy and diffuse thinning of the glomerular basement membrane by electron microscopy. Without any treatment, her proteinuria improved (protein 2+).</p>
<p>By the time of 7&#x2009;years old, she had no ability of walking steadily, running and jumping with fine motor regression. She could pronounce, but could not form sentences. She was incapable of understanding and executing instruction correctly. During follow-up, renal function remained normal.</p>
</sec>
<sec id="sec11">
<label>3.1.3</label>
<title>Patient 3</title>
<p>A now-10-year-old male was born after a normal pregnancy and delivered uneventfully. From infancy, the patient presented with delays in motor function, language, and cognition, with a significant language delay. At age of 2&#x2009;years, focal motor seizure was first observed. Physical examination revealed generalized hypotonia, stereotypic movements. Interictal EEG demonstrated slow background activity and multifocal spike discharges. Ictal EEG revealed high-voltage slow waves followed attenuation, fast rhythms, resembling epileptic spasms. Urinalysis confirmed nephrotic range proteinuria with normal serum creatine and albumin. The patient also had an extensive medical history including trauma history and completed metabolic disease screening, brain MRI, chromosome karyotype, renal ultrasound and other related examinations. No other identifiable clinical or molecular abnormalities were found. Despite the application of valproate, topiramate, levetiracetam, and lamotrigine, seizures were not controlled satisfactory. Seizures were improved from 8&#x2009;years old. The renal function remained normal.</p>
</sec>
</sec>
<sec id="sec12">
<label>3.2</label>
<title>Genetic analysis</title>
<p>Two <italic>de novo</italic> heterozygous truncating variants were identified in <italic>TRIM8</italic> gene, including c.1327_c.1328delCCinsTG (p.R443&#x002A;) (Patient 1), c.1375C&#x003E;T (p.Gln459&#x002A;) (Patients 2 and 3) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). c.1327_c.1328delCCinsTG was not reported and the other variant was reported (<xref ref-type="bibr" rid="ref2">2</xref>, <xref ref-type="bibr" rid="ref11">11</xref>, <xref ref-type="bibr" rid="ref14">14</xref>). The variants were all located in exon 6 and lead to the early termination of protein translation encoded by <italic>TRIM8</italic> gene. The two variants were absent in population databases including the Exome Aggregation Consortium database (ExAC),<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> Genome Aggregation Database (gnomAD),<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref> 1,000 Genomes (1000G).<xref ref-type="fn" rid="fn0003"><sup>3</sup></xref> The two variants had an ACMG score of PVS1_strong + PS2_very strong + PM2_ supporting + PP3 and were classified as pathogenic variants (<xref ref-type="bibr" rid="ref15">15</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Pathogenic <italic>TRIM8</italic> variants. Protein domain structure of TRIM8 (NP_112174.2) and variants positions: RING-finger domain, two B-boxes (B-box1 and B-box2), a coiled-coil domain, and a proline-rich C-terminal region with a nuclear localization signal (NLS).</p>
</caption>
<graphic xlink:href="fneur-15-1410187-g001.tif"/>
</fig>
</sec>
<sec id="sec13">
<label>3.3</label>
<title>Results on literature search</title>
<p>As of December 2023, a total of 24 patients with <italic>TRIM8</italic>-related NRS have been reported (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref2">2</xref>, <xref ref-type="bibr" rid="ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14">7&#x2013;14</xref>), with 18 different truncating variants of the <italic>TRIM8</italic> gene detected (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The major clinical features of the 24 cases are provided in <xref ref-type="table" rid="tab1">Table 1</xref>. The 24 patients include 12 males and 12 females. Among them, three patients involved only neurological diseases, two involved only renal diseases, and the other 19 involved both neurological and renal systems.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Clinical features of patients with <italic>TRIM8</italic> variants.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Variants</th>
<th align="center" valign="middle">Gender</th>
<th align="center" valign="middle">Epilepsy onset (y)</th>
<th align="left" valign="middle">Seizure type</th>
<th align="center" valign="middle">DRE</th>
<th align="left" valign="middle">EEG</th>
<th align="left" valign="middle">Brian MRI</th>
<th align="left" valign="middle">Other features</th>
<th align="left" valign="middle">Renal feature</th>
<th align="left" valign="middle">ERSD<break/>Onset<break/>(y)</th>
<th align="left" valign="middle">Facial appearance</th>
<th align="center" valign="middle">Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">c. 1099_1100insG<break/>p. Cys367Trpfs&#x002A;43</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">0.2</td>
<td align="left" valign="top">Focal motor seizures</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">Atypical hypsarrhythmia evolved into focal spike discharge</td>
<td align="left" valign="top">Normal</td>
<td align="left" valign="top">DD, ASD, microcephaly</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">Small, upper-slanted<break/>palpebral fissures, long-arched eyebrows, thin lips, relatively large ear lobes</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref8">8</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1117_1117delG<break/>p. Ala374Argfs&#x002A;16</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">0.4</td>
<td align="left" valign="top">Absence with myoclonias, focal motor<break/>seizures</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">Mild CS atrophy<break/>with patchy increase in T2 signal in white matter</td>
<td align="left" valign="top">DD, ASD, hypospadias</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">Long philtrum</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref11">11</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1163delT<break/>p. Phe388Serfs&#x002A;2</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">4.5</td>
<td align="left" valign="top">Generalized tonic&#x2013;clonic seizures</td>
<td align="center" valign="top">NM</td>
<td align="left" valign="top">Rolandic discharges mainly in left region</td>
<td align="left" valign="top">Mild CC atrophy</td>
<td align="left" valign="top">DD</td>
<td align="left" valign="top">SRNS, Bx FSGS</td>
<td align="left" valign="top">3</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1198_1220del<break/>p. Tyr400ArgfsTer&#x002A;2</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">5</td>
<td align="left" valign="top">Generalized seizures</td>
<td align="center" valign="top">NO</td>
<td align="left" valign="top">Normal</td>
<td align="left" valign="top">An old infarct in the superior<break/>aspect of the left cerebellar hemisphere</td>
<td align="left" valign="top">Mild DD, strabismus</td>
<td align="left" valign="top">SRP, hypoalbuminemia,<break/>Bx FSGS</td>
<td align="left" valign="top">5</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref10">10</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1201_1202delGGInsTA<break/>p. Gly401&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">3</td>
<td align="left" valign="top">Atypical febrile seizures</td>
<td align="center" valign="top">NO</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">Mild CC atrophy</td>
<td align="left" valign="top">DD, hypothyroidism</td>
<td align="left" valign="top">SRNS, Bx DMS</td>
<td align="left" valign="top">5</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1231C&#x2009;&#x003E;&#x2009;T<break/>p. Gln411&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">2.5</td>
<td align="left" valign="top">Generalized seizures</td>
<td align="center" valign="top">NM</td>
<td align="left" valign="top">Central left accentuated seizure<break/>pattern</td>
<td align="left" valign="top">Cerebral atrophy</td>
<td align="left" valign="top">DD, hyperopia,<break/>astigmatism, sensorineural hearing<break/>loss</td>
<td align="left" valign="top">SRNS, Bx FSGS</td>
<td align="left" valign="top">4.8</td>
<td align="left" valign="top">Broad forehead,<break/>plagiocephaly, high arched<break/>palate, low set ears</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1240C&#x2009;&#x003E;&#x2009;T<break/>p. Gln414&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">2</td>
<td align="left" valign="top">NM</td>
<td align="center" valign="top">NO</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">Cerebral atrophy</td>
<td align="left" valign="top">DD, hypotonia</td>
<td align="left" valign="top">SRNS, Bx DMS</td>
<td align="left" valign="top">1.1</td>
<td align="left" valign="top">NM</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1267C&#x2009;&#x003E;&#x2009;T<break/>p. Gln423&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">2</td>
<td align="left" valign="top">Focal seizures</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">ESES</td>
<td align="left" valign="top">Nonspecific T2<break/>signal abnormalities</td>
<td align="left" valign="top">DD, feeding difficulty</td>
<td align="left" valign="top">NS, hypernatremia, Bx FSGS</td>
<td align="left" valign="top">12</td>
<td align="left" valign="top">NM</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1267C&#x003E;T<break/>p. Gln423&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">1.8</td>
<td align="left" valign="top">Generalized<break/>tonic&#x2013;clonic seizures</td>
<td align="center" valign="top">NM</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">Normal</td>
<td align="left" valign="top">DD, hypotonia</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">Straight eyebrows,<break/>synophrys, sunken<break/>eyes, flat, long philtrum</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref11">11</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1331C&#x003E;A<break/>p. Ser444&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">3.4</td>
<td align="left" valign="top">Focal motor seizures</td>
<td align="center" valign="top">NO</td>
<td align="left" valign="top">Rolandic and bilateral<break/>frontal discharges</td>
<td align="left" valign="top">Bilateral patchy confluent areas of T2 hyperintensity containing tiny cysts in the peritrigonal and frontal white matter</td>
<td align="left" valign="top">DD, ataxia</td>
<td align="left" valign="top">NRP</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref11">11</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1333C&#x2009;&#x003E;&#x2009;T<break/>p. Gln445&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">1.5</td>
<td align="left" valign="top">Tonic&#x2013;clonic seizures</td>
<td align="center" valign="top">NM</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">Posterior fossa<break/>dilatation and cerebral atrophy</td>
<td align="left" valign="top">DD, spastic dystonic quadriplegia, feeding difficulty</td>
<td align="left" valign="top">SRNS, Bx FSGS</td>
<td align="left" valign="top">19.7</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1,338&#x2009;T&#x003E;A<break/>p. Tyr446&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">2</td>
<td align="left" valign="top">Generalized tonic&#x2013;clonic seizures, tonic seizures, atypical absence, head drops, infantile spasms</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">Multifocal repetitive spike&#x2013;wave activity</td>
<td align="left" valign="top">Delayed myelination</td>
<td align="left" valign="top">DD, hypotonia, feeding difficulty, stereotypic behavior, ataxia</td>
<td align="left" valign="top">SRNS, Bx mesangial glomerulonephritis with IgM deposits</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">Gingival overgrowth,<break/>synophrys, long philtrum</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref11">11</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1375C&#x003E;T<break/>p. Gln459&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">NM</td>
<td align="left" valign="top">Rolandic discharge<break/>(ESES)</td>
<td align="left" valign="top">Hypomyelination at the anterior limb of the bilateral internal<break/>capsule and the<break/>bifrontal lobes white matter</td>
<td align="left" valign="top">DD, hypotonia, hyporeflexia, microcephaly</td>
<td align="left" valign="top">Proteinuria, spontaneously resolved</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref11">11</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1375C&#x003E;T<break/>p. Gln459&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">2</td>
<td align="left" valign="top">Focal motor seizures</td>
<td align="center" valign="top">NO</td>
<td align="left" valign="top">Slow background, Rolandic discharge<break/>(ESES)</td>
<td align="left" valign="top">Mild cerebral atrophy</td>
<td align="left" valign="top">DD, hypotonia, ASD</td>
<td align="left" valign="top">SRNS, Bx FSGS</td>
<td align="left" valign="top">5.3</td>
<td align="left" valign="top">Broad nasal bridge, bilateral low set ears, widespread nipples</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1375C&#x003E;T<break/>p. Gln459&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">2.5</td>
<td align="left" valign="top">atypical absences, atonic seizures</td>
<td align="center" valign="top">NO</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">normal</td>
<td align="left" valign="top">DD, ASD, microcephaly</td>
<td align="left" valign="top">NRP, hypertension, Bx FSGS</td>
<td align="left" valign="top">9.8</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1375C&#x003E;T<break/>p. Gln459&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">2.5</td>
<td align="left" valign="top">NM</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">mesial temporal<break/>sclerosis</td>
<td align="left" valign="top">DD, astigmatism, amblyopia,<break/>Pseudostrabismu-s, hypothyroidism</td>
<td align="left" valign="top">NS, Bx FSGS</td>
<td align="left" valign="top">5</td>
<td align="left" valign="top">Micrognatia</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c. 1375C&#x003E;T<break/>p. Gln459&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">2.5</td>
<td align="left" valign="top">generalized tonic&#x2013;clonic seizures</td>
<td align="center" valign="top">NO</td>
<td align="left" valign="top">normal</td>
<td align="left" valign="top">normal</td>
<td align="left" valign="top">DD, ASD, hypothyroidism</td>
<td align="left" valign="top">SRNS</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref14">14</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1380&#x2009;T&#x2009;&#x003E;&#x2009;A<break/>p. Tyr460&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">2.4</td>
<td align="left" valign="top">focal tonic&#x2013;clonic seizures</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">normal</td>
<td align="left" valign="top">DD</td>
<td align="left" valign="top">SRNS, Bx FSGS</td>
<td align="left" valign="top">&#x003E;5</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref12">12</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1380&#x2009;T&#x2009;&#x003E;&#x2009;G<break/>p. Tyr460&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">1.5</td>
<td align="left" valign="top">focal seizures</td>
<td align="center" valign="top">NO</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">CCB atrophy</td>
<td align="left" valign="top">DD, hypotonia</td>
<td align="left" valign="top">NRP, Bx FSGS</td>
<td align="left" valign="top">8</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1453\u00B0C&#x2009;&#x003E;&#x2009;T<break/>p. Gln485&#x2217;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">SRP, mild hematuria, Bx glomerular segmental mesangial proliferative<break/>lesions with IgA deposit</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref13">13</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1461C&#x2009;&#x003E;&#x2009;G<break/>p. Tyr487&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">Mild DD, hypotonia, Tourette&#x2019;s<break/>syndrome-like symptoms,<break/>ASD</td>
<td align="left" valign="top">SRNS, Bx FSGS</td>
<td align="left" valign="top">14</td>
<td align="left" valign="top">NM</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref2">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1461C&#x2009;&#x003E;&#x2009;A<break/>p. Tyr487&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">Normal</td>
<td align="left" valign="top">normal</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">NS, polyuria, polydipsia, Bx FSGS and cystic dilatation of distal tubules</td>
<td align="left" valign="top">8</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref7">7</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1461C&#x2009;&#x003E;&#x2009;A<break/>p. Tyr487&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">Normal</td>
<td align="left" valign="top">Normal</td>
<td align="left" valign="top">Mild DD</td>
<td align="left" valign="top">SRNS, hypertension (convulsion twice), Bx FSGS</td>
<td align="left" valign="top">6</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref13">13</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">c.1484G&#x2009;&#x003E;&#x2009;A<break/>p. Trp495&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">None</td>
<td align="left" valign="top">NM</td>
<td align="left" valign="top">Bilateral frontal<break/>extracerebral space widened, left ventricle fuller than right ventricle, an arachnoid cyst in the cisterna magna</td>
<td align="left" valign="top">Neurogenic bladder (relieved by Solifenacin), astigmatism, myopia</td>
<td align="left" valign="top">SRNS, Bx FSGS and cystic dilatation of renal tubules</td>
<td align="left" valign="top">6</td>
<td align="left" valign="top">Low-set ears, micrognathia, thin lips, wide eye distance, stubby neck, and large ear lobes</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="ref9">9</xref>)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="12">Our patient</td>
</tr>
<tr>
<td align="left" valign="top">c.1327_c.1328delCCinsTG<break/>p. Arg443&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">2.1</td>
<td align="left" valign="top">focal motor seizures</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">Rolandic discharge<break/>(ESES)</td>
<td align="left" valign="top">Normal</td>
<td align="left" valign="top">DD, hypotonia, feeding difficulty</td>
<td align="left" valign="top">NRP, Bx minimal change disease</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">Long philtrum, odontodysplasia</td>
<td align="center" valign="top">P1</td>
</tr>
<tr>
<td align="left" valign="top">c. 1375C&#x003E;T<break/>p. Gln459&#x002A;</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">1.8</td>
<td align="left" valign="top">focal motor seizures</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">Slow background, diffuse spike-and-waves<break/>(ESES)</td>
<td align="left" valign="top">Periventricular leukomalacia</td>
<td align="left" valign="top">DD, stereotypic behavior, hypotonia</td>
<td align="left" valign="top">NS hyperuricemia, Bx minimal change disease</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">P2</td>
</tr>
<tr>
<td align="left" valign="top">c. 1375C&#x003E;T<break/>p. Gln459&#x002A;</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">2</td>
<td align="left" valign="top">Infantile spasms, focal motor seizures</td>
<td align="center" valign="top">YES</td>
<td align="left" valign="top">Slow background, multifocal spike discharge</td>
<td align="left" valign="top">Normal</td>
<td align="left" valign="top">DD, hypotonia, stereotypic behavior</td>
<td align="left" valign="top">NRP</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">None</td>
<td align="center" valign="top">P3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>M, male; F, female; DRE, drug-resistant epilepsy; DD, developmental delay; ASD, autism spectrum disorder; NM, not mentioned; NA, not available; Bx, biopsy; CS, cortical and subcortical; CC, cerebral and cerebellar; SRNS, steroid-resistant nephrotic syndrome; SRP, steroid-resistant proteinuria; ESRD, end-stage renal disease; FSGS, focal segmental glomerulosclerosis; CCB, cerebral, cerebellar and brainstem; NRP, nephrotic-range proteinuria; ESES,electrical status epilepticus during sleep.</p>
</table-wrap-foot>
</table-wrap>
<p>18 (75%) of 24 patients developed epilepsy with seizure onset ranging from 0.2 to 5&#x2009;years. Three patients presented various seizure types during the course of the disease, including focal motor seizures, tonic seizures, generalized tonic&#x2013;clonic seizures, absence with myoclonias, atypical absence seizures, atonic seizures and epileptic spasms. Interictal EEGs varied from normal, to focal discharges, Rolandic discharges, slow background with multifocal spike discharges, and atypical hypsarrhythmia. Three patients reached ESES and one patient had no seizure attack. Brain MRI changes documented in 15 (68%) of 22 patients with available data included varying degrees of brain atrophy (<italic>n</italic>&#x2009;=&#x2009;8), hypomyelination (<italic>n</italic>&#x2009;=&#x2009;2), mesial temporal sclerosis (<italic>n</italic>&#x2009;=&#x2009;1). In addition, drug-resistant epilepsy occurred in 6 of 14 (42%) patients with available data on anti-epilepsy treatment. Furthermore, DD (<italic>n</italic>&#x2009;=&#x2009;21), hypotonia (<italic>n</italic>&#x2009;=&#x2009;7), autism spectrum disorder (<italic>n</italic>&#x2009;=&#x2009;6), feeding difficulty (<italic>n</italic>&#x2009;=&#x2009;3), microcephaly (<italic>n</italic>&#x2009;=&#x2009;3), ataxia (<italic>n</italic>&#x2009;=&#x2009;2), neurogenic bladder (<italic>n</italic>&#x2009;=&#x2009;1) and spastic dystonic quadriplegia (<italic>n</italic>&#x2009;=&#x2009;1) were observed.</p>
<p>21 (87.5%) of 24 patients developed renal manifestation including asymptomatic proteinuria, nephrotic-range proteinuria or typical nephrotic syndrome. 16 (16/21, 76%) patients eventually progressed to end-stage renal disease occurred at 1.1 to 19.7&#x2009;years. Renal biopsies were performed in 18 patients: two had mesangial glomerulonephritis, two had diffuse mesangial sclerosis, 14 had FSGS.</p>
<p>Specific facial features were observed in eight patients including long philtrum, straight eyebrows, sunken eyes, micrognathia, broad forehead, broad nasal bridge, upper-slanted palpebral fissures, thin lips, large ear lobes, and low-set ears. In addition, astigmatism/myopia/amblyopia/pseudosquinting (<italic>n</italic> =&#x2009;4) and hypothyroidism (<italic>n</italic> =&#x2009;3) were observed.</p>
<p>All 18 <italic>TRIM8</italic> variants were truncating variants, which located in exon 6. Among 24 patients, five individuals shared the identical variant at position Gln459&#x002A; (c.1375&#x2009;T&#x003E;C), three at position Tyr487&#x002A; (c.1461C&#x003E;A/G), two at position Tyr423&#x002A; (c.1267C&#x003E;T) and two at position Tyr460&#x002A;(c.1380&#x2009;T&#x003E;A/G).</p>
</sec>
</sec>
<sec sec-type="discussion" id="sec14">
<label>4</label>
<title>Discussion</title>
<p><italic>TRIM8</italic>-related NRS is an autosomal dominant disorder caused by truncating variants of the <italic>TRIM8</italic> gene, with only 24 patients and 18 genetic variants reported to date (<xref ref-type="bibr" rid="ref2">2</xref>, <xref ref-type="bibr" rid="ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14">7&#x2013;14</xref>). In the present study, we report three patients with <italic>de novo TRIM8</italic> truncating variants. By combining 24 patients in previous reports, a total of 27 patients with <italic>TRIM8</italic>-related NRS are reviewed herein, better understanding the clinical characteristic in children.</p>
<p>The most common neurological presentations included DD (89%) and epilepsy (78%). In the patients with clinical information, focal seizure was the most frequent seizure type (57%). 19% of patients developed various seizure types during the course of the disease, one of whom could be diagnosed as Lennox&#x2013;Gastaut syndrome. 52% of patients presented drug-resistant epilepsy among the 17 patients with available data on anti-epilepsy treatment. Our three patients all had intractable seizures with 3 to 6 anti-seizure medication. With ongoing brain maturation, improvements in seizure activity were found. DD was noted before or after seizure onset, and developmental regression was found in some patients. This phenomenon suggested that developmental impairment was due to both the etiology and superimposed epileptic activities. Language impairment was the most frequent concern in our three patients. The implementation of speech and language therapy is crucial for improving the prognosis. EEGs exhibited no specific abnormalities. It is worth noting that four patients developed ESES, three patients of whom shared the identical variant at position Gln459&#x002A;. Among 25 patients whose neuroimaging information could be obtained, 64% exhibited non-specific brain MRI abnormalities. Brain atrophy was the most common change (50%).</p>
<p>Renal diseases are the most recurrent feature of NRS (89%). 67% of patients eventually progressed to ESRD. FSGS was observed in 70% of patients who underwent renal biopsy. The present three patients developed nephrotic-range protein or nephrotic syndrome with normal renal function. Renal biopsies were performed for two patients. Both revealed minimal change disease, which suggested that renal pathology had the potential to serve as a prognostic indicator for long-term outcomes. Renal diseases occur at the same time as or after nervous system diseases. Therefore, a routine urinalysis is necessary for epileptic patients.</p>
<p>Specific facial features were observed in 33% patients, including long philtrum, straight eyebrows, sunken eyes, micrognathia, broad forehead, broad nasal bridge, upper-slanted palpebral fissures, thin lips, large ear lobes, and low-set ears. In addition, other clinical features could be observed, including astigmatism/myopia/amblyopia/pseudosquinting and hypothyroidism. Evaluation of other organs, including eye and thyroid, is essential in <italic>TRIM8</italic>-related NRS patients.</p>
<p>Altogether, 19 <italic>TRIM8</italic> truncating variants were detected including nonsense variants (79%) and frameshift variants (21%). All variants clustered within the last exon between residues 367 and 495 of the 551 amino acid protein. Reviewing 27 patients demonstrated that seven individuals shared the identical variant at position Gln459&#x002A;, three at position Tyr487&#x002A;, two at position Tyr423&#x002A; and two at position Tyr460&#x002A;. Two patients reported by Sakai et al. (Cys367Trpfs&#x002A;43) and Assoum et al. (Ala374Argfs&#x002A;16), which were closer to the N-terminal, had drug resistant epilepsy, developmental delay and ASD, but without renal damage (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref11">11</xref>). Five patients with variants loci at Gln485&#x2217;, Gln487&#x2217; and Gln495&#x2217;, which were closer to the C-terminal, had no seizure attack (<xref ref-type="bibr" rid="ref2">2</xref>, <xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref9">9</xref>, <xref ref-type="bibr" rid="ref13">13</xref>). Among the five patients, two had mild DD and one had neurogenic bladder, which suggested slight involvement of the nervous system. The recurrent variant Gln459&#x002A; was the most common variant of <italic>TRIM8</italic>, which was found in 7 of 27 patients (25.9%). Six patients developed epilepsy and DD, while the remaining one was diagnosed with ESES without seizure attack. One patient reported by Sun X et al. had seizure spontaneously relieved without anti-seizure medication (<xref ref-type="bibr" rid="ref14">14</xref>). Both our patients had drug-resistant epilepsy. Similarly, the severity of the renal phenotype was variable, ranging from proteinuria spontaneously resolved to ERSD during follow-up. It suggested that phenotype with the same variant locus might differ in their severity.</p>
<p>TRIM8 or RING finger protein 27 (RNF27) is encoded by the <italic>TRIM8</italic> gene which positioned on the chromosome 10q24.32. TRIM8 protein is ubiquitously expressed in various adult human tissues, especially localized to the nuclear bodies of renal podocytes and neuronal cells. Hence the main clinical features of NRS include the renal and neurodevelopmental phenotype. TRIM8 interacts with the suppressor of cytokine signaling-1(SOCS-1), which is mediated by the C-terminal region. Co-expression of TRIM8 with SOCS-1 decreases the stability and thus the levels of SOCS-1. The reduced expression of SOCS-1 correlates with decreased inhibition of IFN-<italic>&#x03B3;</italic>-induced JAK&#x2013;STAT activation (<xref ref-type="bibr" rid="ref16">16</xref>). Both Warren et al. and Shirai et al. reported the observation of strong staining of SOCS1 protein with anti-SOCS1 antibodies in kidney from their patient, which confirmed this mechanism (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref12">12</xref>). However, the relationship between the TRIM8, SOCS1 protein expression, and renal manifestations remain unknown. Furthermore, wild-type TRIM8 localized to discrete nuclear bodies, while TRIM8 bearing truncating variants in the C-terminus mis-localized diffusely to the nucleoplasm (<xref ref-type="bibr" rid="ref4">4</xref>). However, the cellular role of endogenous TRIM8 in these nuclear bodies remains unknow.</p>
</sec>
<sec sec-type="conclusions" id="sec15">
<label>5</label>
<title>Conclusion</title>
<p>This study reported one novel truncating variant, expanding the variants spectrum. TRIM8 protein is highly expressed in renal podocytes and neuronal cells. <italic>TRIM8</italic> gene mutation should be cautioned in children with epilepsy, DD, and proteinuria. Gln459&#x002A; variant is the most common variant. Neurological and renal phenotype with the same variant locus may differ in their severity. Further research is needed to explore the relationship between genotype and phenotype of <italic>TRIM8</italic> variants.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec16">
<title>Data availability statement</title>
<p>The data presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.</p>
</sec>
<sec sec-type="ethics-statement" id="sec17">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Ethics Committee of Peking University People&#x2019;s Hospital, approval number: 2023PHB245-001. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin. Written informed consent was obtained from the individual(s), and minor(s)&#x2019; legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec sec-type="author-contributions" id="sec18">
<title>Author contributions</title>
<p>QL: Methodology, Investigation, Conceptualization, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft. YN: Writing &#x2013; review &#x0026; editing, Investigation. ZX: Writing &#x2013; review &#x0026; editing, Investigation. JQ: Writing &#x2013; review &#x0026; editing, Supervision, Methodology. ZY: Writing &#x2013; review &#x0026; editing, Visualization, Project administration.</p>
</sec>
<sec sec-type="funding-information" id="sec19">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. National Natural Science Foundation of China Grant: 82171436; Beijing Health Promotion Research Fund Project (2020-2-4077); 2018 Beijing Clinical Key Specialty Construction Project - Pediatrics Foundation (2199000726); People&#x2019;s Hospital School Construction Project (BMU2023XY016); Peking University People&#x2019;s Hospital Talent Introduction Start-up Fund (2023-T-02); Peking University People&#x2019;s Hospital R&#x0026;D Fund Unveiling Project (RDGS2023-10).</p>
</sec>
<ack>
<p>The authors thank all the patients and their families for participating.</p>
</ack>
<sec sec-type="COI-statement" id="sec20">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="sec21">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn id="fn0001"><p><sup>1</sup><ext-link xlink:href="http://exac.broadinstitute.org" ext-link-type="uri">http://exac.broadinstitute.org</ext-link></p></fn>
<fn id="fn0002"><p><sup>2</sup><ext-link xlink:href="http://gnomad.broadinstitute.org" ext-link-type="uri">http://gnomad.broadinstitute.org</ext-link></p></fn>
<fn id="fn0003"><p><sup>3</sup><ext-link xlink:href="http://asia.ensembl.org/Homo_sapiens/Info/Index" ext-link-type="uri">http://asia.ensembl.org/Homo_sapiens/Info/Index</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname> <given-names>AS</given-names></name> <name><surname>Berkovic</surname> <given-names>SF</given-names></name> <name><surname>Cossette</surname> <given-names>P</given-names></name> <name><surname>Delanty</surname> <given-names>N</given-names></name> <name><surname>Dlugos</surname> <given-names>D</given-names></name> <name><surname>Eichler</surname> <given-names>EE</given-names></name> <etal/></person-group>. <article-title>De novo mutations in epileptic encephalopathies</article-title>. <source>Nature</source>. (<year>2013</year>) <volume>501</volume>:<fpage>217</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature12439</pub-id></citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname> <given-names>PL</given-names></name> <name><surname>Majmundar</surname> <given-names>AJ</given-names></name> <name><surname>Khan</surname> <given-names>K</given-names></name> <name><surname>Lim</surname> <given-names>TY</given-names></name> <name><surname>Shril</surname> <given-names>S</given-names></name> <name><surname>Jin</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis</article-title>. <source>Am J Hum Genet</source>. (<year>2021</year>) <volume>108</volume>:<fpage>357</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajhg.2021.01.008</pub-id>, PMID: <pub-id pub-id-type="pmid">33508234</pub-id></citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhaduri</surname> <given-names>U</given-names></name> <name><surname>Merla</surname> <given-names>G</given-names></name></person-group>. <article-title>Rise of TRIM8: a molecule of duality</article-title>. <source>Mol Ther Nucleic Acids</source>. (<year>2020</year>) <volume>22</volume>:<fpage>434</fpage>&#x2013;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.omtn.2020.08.034</pub-id>, PMID: <pub-id pub-id-type="pmid">33230447</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reymond</surname> <given-names>A</given-names></name> <name><surname>Meroni</surname> <given-names>G</given-names></name> <name><surname>Fantozzi</surname> <given-names>A</given-names></name> <name><surname>Merla</surname> <given-names>G</given-names></name> <name><surname>Cairo</surname> <given-names>S</given-names></name> <name><surname>Luzi</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>The tripartite motif family identifies cell compartments</article-title>. <source>EMBO J</source>. (<year>2001</year>) <volume>20</volume>:<fpage>2140</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1093/emboj/20.9.2140</pub-id>, PMID: <pub-id pub-id-type="pmid">11331580</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caratozzolo</surname> <given-names>MF</given-names></name> <name><surname>Marzano</surname> <given-names>F</given-names></name> <name><surname>Mastropasqua</surname> <given-names>F</given-names></name> <name><surname>Sbis&#x00E0;</surname> <given-names>E</given-names></name> <name><surname>Tullo</surname> <given-names>A</given-names></name></person-group>. <article-title>TRIM8: making the right decision between the oncogene and tumour suppressor role</article-title>. <source>Genes (Basel)</source>. (<year>2017</year>) <volume>8</volume>:<fpage>354</fpage>. doi: <pub-id pub-id-type="doi">10.3390/genes8120354</pub-id>, PMID: <pub-id pub-id-type="pmid">29182544</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carinci</surname> <given-names>F</given-names></name> <name><surname>Arcelli</surname> <given-names>D</given-names></name> <name><surname>Lo</surname> <given-names>ML</given-names></name> <name><surname>Francioso</surname> <given-names>F</given-names></name> <name><surname>Valentini</surname> <given-names>D</given-names></name> <name><surname>Evangelisti</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Molecular classification of nodal metastasis in primary larynx squamous cell carcinoma</article-title>. <source>Transl Res</source>. (<year>2007</year>) <volume>150</volume>:<fpage>233</fpage>&#x2013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.trsl.2007.03.011</pub-id>, PMID: <pub-id pub-id-type="pmid">17900511</pub-id></citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname> <given-names>Y</given-names></name> <name><surname>Miura</surname> <given-names>K</given-names></name> <name><surname>Kaneko</surname> <given-names>N</given-names></name> <name><surname>Ishizuka</surname> <given-names>K</given-names></name> <name><surname>Endo</surname> <given-names>A</given-names></name> <name><surname>Hashimoto</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>A novel de novo truncating TRIM8 variant associated with childhood-onset focal segmental glomerulosclerosis without epileptic encephalopathy: a case report[J]</article-title>. <source>BMC Nephrol</source>. (<year>2021</year>) <volume>22</volume>:<fpage>417</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12882-021-02626-1</pub-id>, PMID: <pub-id pub-id-type="pmid">34930159</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname> <given-names>Y</given-names></name> <name><surname>Fukai</surname> <given-names>R</given-names></name> <name><surname>Matsushita</surname> <given-names>Y</given-names></name> <name><surname>Miyake</surname> <given-names>N</given-names></name> <name><surname>Saitsu</surname> <given-names>H</given-names></name> <name><surname>Akamine</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>De novo truncating mutation of TRIM8 causes early-onset epileptic encephalopathy[J]</article-title>. <source>Ann Hum Genet</source>. (<year>2016</year>) <volume>80</volume>:<fpage>235</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ahg.12157</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name> <name><surname>Guo</surname> <given-names>H</given-names></name></person-group>. <article-title>De novo truncating variants of TRIM8 and atypical neuro-renal syndrome: a case report and literature review</article-title>. <source>Ital J Pediatr</source>. (<year>2023</year>) <volume>49</volume>:<fpage>46</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13052-023-01453-4</pub-id>, PMID: <pub-id pub-id-type="pmid">37061734</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McClatchey</surname> <given-names>MADTZ</given-names></name></person-group>. <article-title>Focal segmental glomerulosclerosis and mild intellectual disability in a patient with a novel de novo truncating TRIM8 mutation</article-title>. <source>Eur J Med Chem</source>. (<year>2020</year>) <volume>63</volume>:<fpage>103972</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejmg.2020.103972</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assoum</surname> <given-names>M</given-names></name> <name><surname>Lines</surname> <given-names>MA</given-names></name> <name><surname>Elpeleg</surname> <given-names>O</given-names></name> <name><surname>Darmency</surname> <given-names>V</given-names></name> <name><surname>Whiting</surname> <given-names>S</given-names></name> <name><surname>Edvardson</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Further delineation of the clinical spectrum of de novo TRIM8 truncating mutations</article-title>. <source>Am J Med Genet A</source>. (<year>2018</year>) <volume>176</volume>:<fpage>2470</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ajmg.a.40357</pub-id></citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname> <given-names>MTMPA</given-names></name></person-group>. <article-title>Association of a de novo nonsense mutation of the TRIM8 gene with childhood-onset focal segmental glomerulosclerosis[J]</article-title>. <source>Pediatr Nephrol</source>. (<year>2020</year>) <volume>35</volume>:<fpage>1129</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00467-020-04525-3</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name> <name><surname>Wei</surname> <given-names>Y</given-names></name> <name><surname>Wang</surname> <given-names>M</given-names></name> <name><surname>Jia</surname> <given-names>L</given-names></name> <name><surname>Shi</surname> <given-names>Z</given-names></name> <name><surname>Yang</surname> <given-names>X</given-names></name> <etal/></person-group>. <article-title>Two children with steroid-resistant significant proteinuria due to nonsense mutations of the TRIM8 gene: a case report and literature review</article-title>. <source>Front Pediatr</source>. (<year>2022</year>) <volume>10</volume>:<fpage>918373</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fped.2022.918373</pub-id>, PMID: <pub-id pub-id-type="pmid">35903163</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>X</given-names></name> <name><surname>Xin</surname> <given-names>M</given-names></name> <name><surname>Tian</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name> <name><surname>Jiao</surname> <given-names>Q</given-names></name> <name><surname>Yang</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Genetic analysis of a child with focal segmental glomerulosclerosis and neurodevelopmental syndrome</article-title>. <source>Zhonghua Yi Xue Yi Chuan Xue Za Zhi</source>. (<year>2023</year>) <volume>40</volume>:<fpage>1155</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.cn511374-20220831-00592</pub-id>, PMID: <pub-id pub-id-type="pmid">37643965</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname> <given-names>S</given-names></name> <name><surname>Aziz</surname> <given-names>N</given-names></name> <name><surname>Bale</surname> <given-names>S</given-names></name> <name><surname>Bick</surname> <given-names>D</given-names></name> <name><surname>das</surname> <given-names>S</given-names></name> <name><surname>Gastier-Foster</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]</article-title>. <source>Genet Med</source>. (<year>2015</year>) <volume>17</volume>:<fpage>405</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id>, PMID: <pub-id pub-id-type="pmid">25741868</pub-id></citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toniato</surname> <given-names>E</given-names></name> <name><surname>Chen</surname> <given-names>XP</given-names></name> <name><surname>Losman</surname> <given-names>J</given-names></name> <name><surname>Flati</surname> <given-names>V</given-names></name> <name><surname>Donahue</surname> <given-names>L</given-names></name> <name><surname>Rothman</surname> <given-names>P</given-names></name></person-group>. <article-title>TRIM8/GERP RING finger protein interacts with SOCS-1[J]</article-title>. <source>J Biol Chem</source>. (<year>2002</year>) <volume>277</volume>:<fpage>37315</fpage>&#x2013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M205900200</pub-id>, PMID: <pub-id pub-id-type="pmid">12163497</pub-id></citation></ref>
</ref-list>
</back>
</article>